


DESCRIPTION	
Species Reactivity	Porcine
Specificity	Detects porcine IFN- γ in direct ELISAs and Western blots. In direct ELISAs, approximately 60% cross-reactivity with recombinant canine IFN- γ and recombinant feline IFN- γ is observed, 10% cross-reactivity with recombinant equine IFN- γ and recombinant human IFN- γ is observed, and less than 5% cross-reactivity with recombinant mouse IFN- γ , recombinant rat IFN- γ , recombinant cotton rat IFN- γ , and recombinant rhesus macaque IFN- γ is observed.
Source	Polyclonal Goat IgG
Purification	Antigen Affinity-purified
Immunogen	<i>E. coli</i> -derived recombinant porcine IFN- γ Ser21-Lys166 Accession # P17803
Endotoxin Level	<0.10 EU per 1 μ g of the antibody by the LAL method.
Formulation	Lyophilized from a 0.2 μ m filtered solution in PBS with Trehalose. See Certificate of Analysis for details. *Small pack size (-SP) is supplied as a 0.2 μ m filtered solution in PBS.

APPLICATIONS

Please Note: Optimal dilutions should be determined by each laboratory for each application. *General Protocols* are available in the *Technical Information* section on our website.

	Recommended Concentration	Sample
Western Blot	0.1 μ g/mL	Recombinant Porcine IFN- γ (Catalog # 985-PI)
Neutralization		Measured by its ability to neutralize IFN- γ inhibition of EMCV-induced cytopathy in the PK-15 porcine kidney epithelial cell line. The Neutralization Dose (ND ₅₀) is typically 0.6-3.0 μ g/mL in the presence of 0.2 ng/mL Recombinant Porcine IFN- γ .

DATA



PREPARATION AND STORAGE

Reconstitution	Reconstitute at 0.2 mg/mL in sterile PBS.
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (-SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C
Stability & Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. <ul style="list-style-type: none"> ● 12 months from date of receipt, -20 to -70 °C as supplied. ● 1 month, 2 to 8 °C under sterile conditions after reconstitution. ● 6 months, -20 to -70 °C under sterile conditions after reconstitution.

BACKGROUND

Interferon-gamma (IFN- γ), also known as type II or immune interferon, exerts a wide range of immunoregulatory activities and is considered to be the prototype proinflammatory cytokine (1, 2). Mature porcine IFN- γ exists as a noncovalently linked homodimer of 20-25 kDa variably glycosylated subunits (3). It shares 72%-79% amino acid sequence identity with bovine, canine, equine, and feline IFN- γ and 41%-57% with cotton rat, human, mouse, rat, and rhesus IFN- γ . IFN- γ dimers bind to IFN- γ RI (α subunits) which then interact with IFN- γ RII (β subunits) to form the functional receptor complex of two α and two β subunits. Inclusion of IFN- γ RII increases the binding affinity for ligand and the efficiency of signal transduction (4, 5). IFN- γ is produced by a variety of immune cells under inflammatory conditions, notably by T cells and NK cells (6). It plays a key role in host defense by promoting the development and activation of Th1 cells, chemoattraction and activation of monocytes and macrophages, upregulation of antigen presentation molecules, and immunoglobulin class switching in B cells. It also exhibits antiviral, anti-proliferative, and apoptotic effects (6, 7). In addition, IFN- γ functions as an anti-inflammatory mediator by promoting the development of regulatory T cells and inhibiting Th17 cell differentiation (8, 9). The pleiotropic effects of IFN- γ contribute to the development of multiple aspects of atherosclerosis (7).

References:

1. Billiau, A. and P. Matthys (2009) *Cytokine Growth Factor Rev.* **20**:97.
2. Pestka, S. *et al.* (2004) *Immunol. Rev.* **202**:8.
3. Dijkmans, R. *et al.* (1990) *Nucl. Acids Res.* **18**:4259.
4. Marsters, S.A. *et al.* (1995) *Proc. Natl. Acad. Sci.* **92**:5401.
5. Krause, C.D. *et al.* (2000) *J. Biol. Chem.* **275**:22995.
6. Schroder, K. *et al.* (2004) *J. Leukoc. Biol.* **75**:163.
7. McLaren, J.E. and D.P. Ramji (2009) *Cytokine Growth Factor Rev.* **20**:125.
8. Muhl, H. and J. Pfeilschifter (2003) *Int. Immunopharmacol.* **3**:1247.
9. Kelchtermans, H. *et al.* (2008) *Trends Immunol.* **29**:479.